Neurological Sciences

, Volume 29, Supplement 2, pp 230–232

Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis

  • Mauro Zaffaroni
  • Annalisa Rizzo
  • Silvana Maria Baldini
  • Angelo Ghezzi
  • Giancarlo Comi
Multiple Sclerosis: The Management of Non-Responders

DOI: 10.1007/s10072-008-0946-x

Cite this article as:
Zaffaroni, M., Rizzo, A., Baldini, S.M. et al. Neurol Sci (2008) 29(Suppl 2): 230. doi:10.1007/s10072-008-0946-x

Abstract

We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/ persistently active disease in spite of IFN-β (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

Keywords

Interferon beta Glatiramer acetate Mitoxantrone Combination therapy Induction therapy Rescue therapy 

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Mauro Zaffaroni
    • 1
  • Annalisa Rizzo
    • 1
    • 2
  • Silvana Maria Baldini
    • 1
  • Angelo Ghezzi
    • 1
  • Giancarlo Comi
    • 1
    • 2
  1. 1.Centro Studi Sclerosi MultiplaGallarateItaly
  2. 2.S. Raffaele Hospital and UniversityMilanoItaly

Personalised recommendations